10月23日消息,艾美疫苗(06660)今日盘中股价大涨逾18%,成为港股医药板块及港股通标的的领涨股。截至发稿,艾美疫苗股价报8.31港元,涨幅9.07%,成交金额逾1.24亿港元。
引发艾美疫苗股价大涨的主要原因是其产品研发取得重大进展。艾美疫苗近期公布,公司在研迭代无血清狂犬病疫苗已完成III期临床试验数据揭盲及统计分析。数据显示该疫苗具有良好的免疫原性和安全性,达到预设目标。同时,艾美疫苗指出已建设完成可生产该疫苗的生产车间。截至目前,全球市场上尚未有无血清狂犬病疫苗获批上市,该产品有望成为首个上市无血清狂犬病疫苗,市场前景广阔。
此外,艾美疫苗目前拥有多款重磅疫苗大单品正处于即将上市的关键阶段,包括13价肺炎结合疫苗、无血清狂犬病疫苗及23价肺炎多糖疫苗。同时公司还有多款mRNA疫苗正在申请临床试验。丰富的产品储备有望助力公司未来实现持续高速增长。市场对艾美疫苗的长期增长前景充满期待,因此在产品喜讯公布后股价实现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.